✅   Teva to pay $450M to settle allegations of kickbacks and generic drug price-fixing

Business

Generics giant Teva Pharmaceuticals will pay $450 million over six years to settle two allegations that the company violated the Anti-Kickback Statute and the False Claims Act, the Department of Justice announced Thursday. The payout will resolve two matters, one of which the government filed in 2020 accusing Teva of paying Medicare patients’ copays for its blockbuster multiple sclerosis drug Copaxone while simultaneously raising the price of the drug. That case alleged that Teva paid over $300 million to two foundations between 2006 and at least 2015 to cover the copays. “For far too long, Teva gamed the charitable foundation process by paying kickbacks through two foundations, and with the aid of a specialty pharmacy,” Acting US ...

Endpoints     Oct 11, 2024